Nuvectis PharmaNVCT
NVCT
About: Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Employees: 13
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
181% more capital invested
Capital invested by funds: $7.15M [Q4 2024] → $20M (+$12.9M) [Q1 2025]
45% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $895K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
6% more funds holding
Funds holding: 31 [Q4 2024] → 33 (+2) [Q1 2025]
1.92% more ownership
Funds ownership: 6.84% [Q4 2024] → 8.75% (+1.92%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
48%
upside
Avg. target
$17
68%
upside
High target
$19
88%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 48%upside $15 | Buy Reiterated | 30 Apr 2025 |
Maxim Group Naz Rahman | 68%upside $17 | Buy Initiated | 2 Apr 2025 |
Laidlaw & Co. Yale Jen | 88%upside $19 | Buy Initiated | 17 Mar 2025 |
Financial journalist opinion
Based on 4 articles about NVCT published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
Positive
Zacks Investment Research
1 week ago
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 108.8% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
2 weeks ago
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2025 and provided an update on recent business progress.
Neutral
GlobeNewsWire
3 weeks ago
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology today provided poster presentation highlights for NXP900 from the 2025 American Association for Cancer Research Meeting (2025 AACR). These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome treatment resistance in non-small cell lung cancer (NSCLC).
Neutral
GlobeNewsWire
2 months ago
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.
Neutral
Business Wire
2 months ago
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.
Neutral
Business Wire
2 months ago
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
NEW YORK--(BUSINESS WIRE)---- $NVCT #Pharma--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safe.
Neutral
GlobeNewsWire
3 months ago
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter's option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.
Positive
Seeking Alpha
3 months ago
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
The company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting toxicities. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
Neutral
GlobeNewsWire
3 months ago
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also granted the underwriter a 30-day option to purchase up to 405,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 6, 2025, subject to customary closing conditions.
Charts implemented using Lightweight Charts™